scholarly journals The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: The untold story

Surgery ◽  
2009 ◽  
Vol 146 (4) ◽  
pp. 543-553 ◽  
Author(s):  
Anton I. Skaro ◽  
Colleen L. Jay ◽  
Talia B. Baker ◽  
Edward Wang ◽  
Sarina Pasricha ◽  
...  
2020 ◽  
Vol 86 (10) ◽  
pp. 1363-1367
Author(s):  
Takahiro Ito ◽  
Mina Botros ◽  
Antony Aziz ◽  
Jacob G. Guorgui ◽  
Vatche G. Agopian ◽  
...  

Biliary strictures constitute a major source of morbidity and mortality following liver transplantation (LT). However, studies on the impact of nonanastomotic biliary strictures (NABS) on grafts after LT are limited. 649 patients who underwent LT between January 2013 and June 2017 at our center were retrospectively analyzed and 2.6% (n = 17) of the recipients developed NABS following LT. There were no differences between recipients with and without NABS in indication of LT, graft ischemia time, and type of biliary anastomosis. The incidence of post-LT hepatic artery thrombosis (HAT) (odds ratio [OR]: 15.75, P < .001) and the use of livers from donation after cardiac death (DCD) donors (OR: 8.292, P = .004) were identified as independent significant predictors of NABS by multivariate analysis. Graft survival in those with NABS was significantly worse than in patients without NABS (1-, 3-, and 5-years survival: 64.7%, 57.5%, 0%, vs. 89.8%, 84.0%, 76.4%, P < .001). In conclusion, while the incidence of NABS in our study was relatively low compared to previous reports, NABS was still found to be associated with poor graft survival. Special attention should be paid to NABS occurrence in grafts that develop HAT as well as those from DCD donors.


2011 ◽  
Vol 253 (2) ◽  
pp. 259-264 ◽  
Author(s):  
Colleen L. Jay ◽  
Vadim Lyuksemburg ◽  
Daniela P. Ladner ◽  
Edward Wang ◽  
Juan C. Caicedo ◽  
...  

2011 ◽  
Vol 18 (1) ◽  
pp. 100-111 ◽  
Author(s):  
C. Burcin Taner ◽  
Ilynn G. Bulatao ◽  
Darrin L. Willingham ◽  
Dana K. Perry ◽  
Lena Sibulesky ◽  
...  

2008 ◽  
Vol 14 (5) ◽  
pp. 604-610 ◽  
Author(s):  
Edie Y. Chan ◽  
Les C. Olson ◽  
James A. Kisthard ◽  
James D. Perkins ◽  
Ramasamy Bakthavatsalam ◽  
...  

2019 ◽  
Vol 62 (1) ◽  
pp. 44-51 ◽  
Author(s):  
Mauro Enrique Tun-Abraham ◽  
Kerollos N. Wanis ◽  
Carlos Garcia-Ochoa ◽  
Nathalie Sela ◽  
Hemant Sharma ◽  
...  

2020 ◽  
Vol 1 (19) ◽  
pp. 39-46
Author(s):  
T. V. Pinchuk ◽  
N. V. Orlova ◽  
T. G. Suranova ◽  
T. I. Bonkalo

At the end of 2019, a new coronavirus (SARS-CoV-2) was discovered in China, causing the coronavirus infection COVID-19. The ongoing COVID-19 pandemic poses a major challenge to health systems around the world. There is still little information on how infection affects liver function and the significance of pre-existing liver disease as a risk factor for infection and severe COVID-19. In addition, some drugs used to treat the new coronavirus infection are hepatotoxic. In this article, we analyze data on the impact of COVID-19 on liver function, as well as on the course and outcome of COVID-19 in patients with liver disease, including hepatocellular carcinoma, or those on immunosuppressive therapy after liver transplantation.


Sign in / Sign up

Export Citation Format

Share Document